The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid ...

Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Contract research, development and manufacturing organisation (CRDMO) WuXi XDC Cayman has signed a memorandum of ...

MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global ...

Elevation Oncology shares halted from trading in premarket trading Thursday after it said it will launch strategic options process and lay off the majority of its staff to extend its cash runway.

Disitamab vedotin, an antibody-drug conjugate (ADC), targets HER2-expressing cancer cells. It works by binding to HER2, being ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...